Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.90 0.33 +0.49%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC (RPRX) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Royalty Pharma PLC (RPRX) trades at a EV/EBITDA of 24.7×. Over the past ten years it has ranged from 0.0× (June 2020) to 67.8× (January 2023); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 15.7× 13.73%
FY2024 13.8× 7.91%
FY2023 12.8× (81.17%)
FY2022 67.8× 361.91%
FY2021 14.7× 5.21%
FY2020 13.9× —
FY2019 0.0× —
FY2018 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 22.0× 3.00%
Jun 2026 21.4× 18.51%
Mar 2026 18.0× 15.23%
Dec 2025 15.7× 5.25%
25 more quarters

Against its own ten years

Low 0.0× High 67.8×
Ten-year median 15.8×
Current reading's percentile 83

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
BNTX BioNTech SE Sponsored ADR compare n/m
RVMD Revolution Medicines, Inc. compare n/m
INSM Insmed, Inc. compare n/m
RPRX Royalty Pharma PLC 24.7×
INCY Incyte Corporation compare 27.9×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 28.6×
ARGX argenex SE compare 30.4×
GMAB Genmab A/S Sponsored ADR compare 31.0×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on RPRX